Pyxis Oncology, Inc. $PYXS Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. cut its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 12.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 160,830 shares of the company’s stock after selling 23,872 shares during the period. Goldman Sachs Group Inc. owned approximately 0.26% of Pyxis Oncology worth $158,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PYXS. Acadian Asset Management LLC acquired a new stake in Pyxis Oncology in the first quarter worth approximately $81,000. 683 Capital Management LLC lifted its position in Pyxis Oncology by 32.5% in the first quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock worth $539,000 after purchasing an additional 135,000 shares during the period. Nuveen LLC acquired a new stake in Pyxis Oncology in the first quarter worth approximately $125,000. Pier 88 Investment Partners LLC lifted its position in Pyxis Oncology by 296.6% in the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock worth $383,000 after purchasing an additional 292,370 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in shares of Pyxis Oncology during the 4th quarter valued at $26,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Price Performance

Pyxis Oncology stock opened at $2.20 on Tuesday. The company has a market capitalization of $136.44 million, a price-to-earnings ratio of -1.37 and a beta of 1.14. Pyxis Oncology, Inc. has a one year low of $0.83 and a one year high of $5.39. The company’s fifty day moving average price is $1.50 and its two-hundred day moving average price is $1.26.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The business had revenue of $2.82 million for the quarter. As a group, sell-side analysts anticipate that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Wall Street Zen raised shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a research note on Sunday, August 24th. Guggenheim assumed coverage on shares of Pyxis Oncology in a research note on Wednesday, September 3rd. They set a “buy” rating and a $5.00 target price on the stock. Finally, Zacks Research raised shares of Pyxis Oncology from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.